Vishwas Chavan response rates vary depending on the patient's history of treatment within the metastatic setting. That is if newly diagnosed, chemo-naive or not and how many prior lines of treatment and recurrent progression. For example in previously untreated populations both response and survival rates are higher vs. those previosuly treated. This results are directly proportional to immune checkpoint protein expression. Although it's difficult to tag the word 'cure' to and advanced cancer, prospectively complete remission and cancer-free are certainly in the horizon for Immuno treated cancers like melanoma and NSCLC which are showing consistent data for several years now.

You can research for malignant melanoma, lung cancer, renal cell cancers.